Global Adult Vaccine Market Size By Type (Influenza, Cervical Cancer), By Application (Hospitals, Medical Care Centers), By Region, And Segment Forecasts, 2023 to 2032

arket Overview:

The Global Adult Vaccine Market was valued at USD 22.3 billion in 2023 and is expected to reach USD 41.6 billion by 2031, growing at a CAGR of 7.9% during the forecast period of 2023–2031. Market growth is being driven by increasing awareness about adult immunization, the resurgence of vaccine-preventable diseases, and growing government initiatives to promote lifelong vaccination. Additionally, the development of combination vaccines, growing elderly populations, and expanding travel-related vaccine needs contribute significantly to demand.

Drivers:

Rising Incidence of Vaccine-Preventable Diseases:

Re-emergence of diseases like measles, pertussis, and influenza in adult populations has led to a renewed focus on adult immunization, driving growth in the global adult vaccine market.

Growing Geriatric Population:

With an aging global population, there is increasing vulnerability to diseases such as pneumonia, shingles, and influenza. This demographic trend is boosting demand for age-specific vaccines.

Government Support and Public Health Campaigns:

National immunization programs and awareness campaigns by organizations like WHO and CDC are instrumental in encouraging adult vaccination, especially in the wake of the COVID-19 pandemic.

Restraints:

Vaccine Hesitancy:

Misinformation and distrust around vaccine safety remain significant barriers, particularly in low- and middle-income countries, hampering uptake of adult vaccines.

Limited Access in Developing Regions:

Inadequate healthcare infrastructure, especially in rural areas, limits vaccine availability and accessibility, impeding market penetration in developing regions.

Opportunity:

Development of Novel Vaccines and mRNA Platforms:

Technological advancements such as mRNA-based vaccines open new avenues for adult immunization, especially in cancer, respiratory, and sexually transmitted diseases.

Expansion of Travel and Occupational Health Vaccines:

The resurgence of global travel and occupational health compliance requirements provide growing markets for adult vaccines targeting hepatitis, meningitis, and yellow fever.

Market by Vaccine Type Insights:

Based on vaccine type, the Influenza vaccine segment held the largest share of the market in 2023. The consistent annual demand due to flu seasons, especially among elderly and immunocompromised adults, supports this segment’s dominance. However, the HPV vaccine segment is anticipated to witness the highest growth rate through 2031, driven by rising awareness around HPV-related cancers and expanded adult vaccination guidelines.

Market by End-use Insights:

Hospitals and clinics emerged as the largest end-use segment, accounting for over 60% of the market share in 2023. These facilities remain primary points for vaccine administration, driven by government immunization programs and trusted healthcare providers. Retail pharmacies are expected to grow rapidly due to their convenience and increasing authorization to administer vaccines in countries like the U.S., U.K., and Australia.

Market by Regional Insights:

North America led the global adult vaccine market in 2023, supported by strong healthcare infrastructure, high vaccine coverage, and supportive public policies. Asia-Pacific is projected to register the fastest growth rate over the forecast period due to increasing health awareness, expanding immunization coverage, and rising elderly population in countries like China, Japan, and India.

Competitive Scenario:

Key players in the Global Adult Vaccine Market include Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Moderna Inc., Johnson & Johnson, CSL Limited, Takeda Pharmaceutical Company Limited, Bavarian Nordic, and Novavax Inc. These companies are investing in R&D for novel vaccines and expanding their manufacturing and distribution networks.

Key recent developments include:

In 2023, Pfizer launched a new RSV vaccine for older adults, targeting respiratory disease in the geriatric population.

In 2024, GSK received FDA approval for a combined tetanus-diphtheria-pertussis (Tdap) booster for adults.

In 2025, Moderna initiated Phase III trials for its mRNA-based cytomegalovirus (CMV) vaccine for adults.

Scope of Work – Global Adult Vaccine Market

Key Market Developments:

2023: Pfizer Inc. launched a new RSV vaccine targeting older adults with chronic respiratory conditions.

2024: Sanofi introduced a hexavalent adult vaccine covering six pathogens in a single dose for emerging markets.

2025: Moderna expanded its pipeline with Phase III trials for its first mRNA-based CMV vaccine for adults.

FAQs:

1) What is the current market size of the Global Adult Vaccine Market?

The Global Adult Vaccine Market was valued at USD 22.3 billion in 2023.

2) What is the major growth driver of the Global Adult Vaccine Market?

Rising incidence of vaccine-preventable diseases and an aging global population are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Adult Vaccine Market?

North America holds the largest market share, supported by a strong healthcare system and public health policies.

4) Which segment accounted for the largest market share in the Global Adult Vaccine Market?

The Influenza vaccine segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Adult Vaccine Market?

Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Moderna Inc., and Johnson & Johnson are among the key players.